2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1364

Affect of Obesity on Multi-Biomarker Disease Activity (MBDA) Measurements in Rheumatoid Arthritis (RA) Patients
Abstract Number: 674

Affordability Concerns Prevalent Among Patients with Systemic Lupus Erythematosus (SLE)
Abstract Number: 639

African-American Risk of Proteinuria After SLE Diagnosis Increases Throughout Thirty Years of Followup
Abstract Number: 1266

AGBL3 as a Novel Gene Associated with Hereditary Hypocomplementemic Urticarial Vasculitis and Favorable Response to Rituximab
Abstract Number: 1957

Aggregation of Functional Variants in NOTCH4 Gene Increases SSc Risk
Abstract Number: 2723

Alagille Syndrome and Chronic Arthritis: An International Case Series
Abstract Number: 2778

Alcohol Consumption as a Predictor of the Progression of Spinal Structural Damage in Axial Spondyloarthritis: Data from the Catholic Axial Spondyloarthritis COhort (CASCO)
Abstract Number: 2069

Alcohol Consumption Is Not an Independent Predictor of Fatigue Severity over Time
Abstract Number: 257

Alcohol Use Hospitalizations in People with Gout, Osteoarthritis, Rheumatoid Arthritis, Fibromyalgia, and Low Back Pain Are Increasing: A Time-trends Study Using the U.S. National Data
Abstract Number: 1984

Alendronate-CGS21680 Conjugates Prevent Bone Erosion in a Murine Osteolysis Model but Not in A2A KO Mice
Abstract Number: 1586

All-cause Hospitalizations and Mortality in Systemic Lupus Erythematosus in the US- results from a National Inpatient Database
Abstract Number: 581

Allograft Inflammatory factor-1 Drives Th17 Like Pathologic Signature and Predict Poor Response to TNF Inhibitor in Ankylosing Spondylitis
Abstract Number: 353

Allopurinol Use and Type 2 Diabetes Incidence Among Patients with Gout: A VA Cohort Study
Abstract Number: 2416

ALPN-101, a First-in-Class Dual ICOS/CD28 Antagonist, Suppresses Key Effector Mechanisms Associated with Sjögren’s Syndrome
Abstract Number: 1531

ALPN-101, a First-in-Class Dual ICOS/CD28 Antagonist, Suppresses Key Effector Mechanisms Underlying Rheumatoid and Psoriatic Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].